Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Today, Zacks Investment Ideas feature highlights Palantir PLTR, Tempus AI TEM and Comfort Systems USA FIX. These 3 AI-Relate ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM) . Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company.